Optiscan Advances Head and Neck Imaging Study Ahead of Schedule
Optiscan Imaging has fast-tracked Stage 2 of its pioneering head and neck cancer imaging study, moving into live intraoperative imaging ahead of schedule. This advancement supports FDA regulatory efforts and enhances the company’s AI imaging development.
- Stage 2 of head and neck cancer study begins early
- In vivo imaging during surgery now underway
- Study data to bolster US FDA submissions
- Collaboration with St John of God and Australian Clinical Labs
- Sodium fluorescein used as contrast agent
Early Progress in Groundbreaking Head and Neck Imaging Study
Optiscan Imaging Ltd (ASX:OIL) has accelerated the second stage of its first-in-human head and neck cancer imaging trial at St John of God Murdoch Hospital in Perth. Stage 2, which involves real-time in vivo imaging during surgery using Optiscan’s InVue™ platform supplemented by ex vivo imaging with the InForm™ device, has commenced ahead of schedule. This early transition follows strong initial results from Stage 1 ex vivo imaging and approval from the hospital’s Human Research Ethics Committee.
Clinical and Regulatory Implications of Live Imaging
The study marks a significant step in validating how real-time microscopic imaging can assist surgeons in assessing tissue structures and surgical margins during complex head and neck cancer procedures. By capturing paired imaging and pathology data across fresh, fixed, and in vivo tissues, the research aims to strengthen the evidence base for Optiscan’s upcoming US FDA regulatory submissions. The data will also feed into the company’s oral cancer AI imaging algorithm development, potentially enhancing diagnostic accuracy and surgical decision-making.
Collaboration and Technology Integration
The study is led by head and neck cancer surgeon Dr Chady Sader, who has helped recruit the initial 10 cases that underpinned the accelerated move to Stage 2. Australian Clinical Labs supports the trial by providing pathology specimen analysis using the InForm™ platform. The trial utilises sodium fluorescein as a contrast agent in combination with Optiscan’s imaging devices, leveraging prior collaboration agreements with Australian Clinical Labs and Long Grove Pharmaceuticals. CEO Dr Camile Farah highlighted the ease of integrating these platforms into existing surgical and pathology workflows, underscoring the strength of the partnerships involved.
Commercial and Strategic Significance
Beyond clinical validation, the study’s progress supports Optiscan’s broader commercial ambitions. Demonstrating workflow integration in a complex surgical oncology setting could pave the way for wider adoption of Optiscan’s InVue™ and InForm™ devices across precision surgery and digital pathology applications. The imaging data generated is expected to contribute to multiple strategic priorities, including AI development and future US clinical activities. This momentum follows the company’s recent regulatory advances, including its FDA dossier submission for the veterinary InSpecta™ device and ongoing clinical trials with InVue™ and InForm™ platforms.
Bottom Line?
Optiscan’s head and neck cancer imaging study is gaining clinical and regulatory traction, but the timeline and impact of FDA approvals remain pivotal for future commercial success.
Questions in the middle?
- How will the accelerated Stage 2 impact the overall timeline for FDA approval?
- What are the potential challenges in scaling real-time imaging technology across diverse surgical settings?
- How might data from this study influence the development and accuracy of Optiscan’s AI imaging algorithms?
